Developing Interventions for Protecting HIV-Exposed Uninfected Infants Against Severe Infections
Launched by UNIVERSITY OF COLORADO, DENVER · Jun 26, 2025
Trial Information
Current as of July 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
1. The study will enroll 24 pregnant women with HIV at 36 weeks gestational age and randomize them 1:1 to receive 500 ml daily of pasteurized fermented milk (Inkomasi) or not. Changes in maternal gut microbiota from enrollment to 2-4 weeks postpartum will be compared between groups. The study will also compare the gut microbiome at infants born to mothers who received Inkomasi with those born to mothers who did not receive Inkomasi.
2. The study will enroll 24 HIV-exposed uninfected infants (HEU) at 24 weeks of age and randomize them 1:1 to receive ≥15 ml daily of pasteurized fermented milk...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Pregnant women with HIV HIV-exposed uninfected infants
- Exclusion Criteria:
- • -
About University Of Colorado, Denver
The University of Colorado, Denver, is a leading academic institution dedicated to advancing medical research and improving healthcare outcomes. With a strong emphasis on innovation and collaboration, the university conducts a diverse range of clinical trials aimed at addressing critical health challenges. Its research initiatives are supported by a multidisciplinary team of experts, state-of-the-art facilities, and a commitment to ethical standards and patient safety. By fostering partnerships with local and global communities, the University of Colorado, Denver, strives to translate scientific discoveries into meaningful advancements in clinical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Johannesburg, , South Africa
Patients applied
Trial Officials
Adriana Weinberg, MD
Principal Investigator
AMC UCD
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported